Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
| Autor: | Élez, E., Kocáková, I., Höhler, T., Martens, U.M., Bokemeyer, C., Van Cutsem, E., Melichar, B., Smakal, M., Csőszi, T., Topuzov, E., Orlova, R., Tjulandin, S., Rivera, F., Straub, J., Bruns, R., Quaratino, S., Tabernero, J. * |
|---|---|
| Zdroj: | In Annals of Oncology January 2015 26(1):132-140 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|